Stock

Panacea Biotec surges 5 per cent on DCGI nod for Sputnik vaccine

Our Burea Mumbai | Updated on July 05, 2021

A flight carrying 56.6 MT shipment of Sputnik V vaccines   -  PTI

The batches produced have successfully met all the quality parameters both at the Gamaleya Center in Russia and at the Central Drug Laboratory, HP

The shares of Panacea Biotec gained 5 per cent in the morning trade on Monday after the company received a manufacturing license from the Drug Controller General (India) for Sputnik V vaccine against Covid-19.

At 11:08 am, Panacea Biotec was trading at ₹396.40 on the BSE, up ₹19.00 or 5.03 per cent. It had opened at ₹400.25 as against the previous close of ₹377.40.It hit an intraday high of ₹411.00 and a low of ₹392.75.

On the NSE, it was trading at ₹396.60, up ₹18.20 or 4.81 per cent

The company on Sunday announced that it has received the manufacturing license from the DCGI for Sputnik V vaccine pursuant to its collaboration with Russian Direct Investment Fund (Russia’s sovereign wealth fund).

The batches produced at Panacea Biotec’s facilities at Baddi, Himachal Pradesh were earlier shipped to the Gamaleya Center in Russia for quality control. These batches have successfully passed all the checks for quality parameters both at the Gamaleya Center in Russia and at the Central Drug Laboratory, Kasauli, Himachal Pradesh in India, the company said in an official release.

Sputnik V was registered in India under the emergency use authorisation procedure on April 12 and for vaccination against Covid-19 that started on May 14. Sputnik V has been registered in 67 countries.

Published on July 05, 2021

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

vaccines and immunisation
stocks and shares
Panacea Biotec Ltd
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.